Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Conditions: Smoldering Multiple Myeloma Sponsors: Tufts Medical Center; National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC
Conditions: Carcinoma; Small Cell Lung Cancer Interventions: Procedure: Drug-eluting beads bronchial arterial chemoembolization; Drug: Serplulimab; Procedure: Intravenous chemotherapy Sponsors: The Central Hospital of Lishui City Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Evaluate the Efficacy of Adding Intraluminal Brachytherapy After CCRT for Local-regional Thoracic Esophageal Cancer.
Conditions: Esophageal Neoplasms; Head and Neck Neoplasms; Gastrointestinal Neoplasms; Digestive System Diseases; Digestive System Neoplasms; Esophageal Diseases; Neoplasms by Site; Gastrointestinal Diseases; Neoplasms Interventions: Device: " BRAXX " Esophageal Brachytherapy Applicator.; Radiation: Add-on of intraluminal brachytherapy Sponsors: Taipei Veterans General Hospital, Taiwan Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in High-risk Patients With Cancer
Conditions: Hypertension Interventions: Device: Cellular enabled blood pressure cuff; Device: Standard of Care Cuff Sponsors: West Michigan Cancer Center; Veta Health Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
Conditions: Nasopharyngeal Carcinoma Interventions: Drug: Sintilimab, bevacizumab, gemcitabine; Radiation: IMRT Sponsors: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
CARE1 Pragmatic Clinical Trial
Conditions: Metastatic Kidney Cancer; Metastatic Kidney Carcinoma Interventions: Drug: Nivolumab; Drug: Ipilimumab; Drug: Pembrolizumab; Drug: Cabozantinib; Drug: Axitinib; Drug: Lenvatinib Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; European Commission; CRIS Cancer Foundation; National Cancer Institute, France; Rennes University Hospital; University Hospital, Essen; Fundaci ó Privada Institut d ' Investigaci ó Oncològica de Vall d ' Hebron; The Netherlands Cancer Institute; Servicio Madrile ño de Salud, Madrid, Spain; Hospital Universitario 12 de Octubre; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan...
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
Conditions: Advanced Solid Tumor; Carcinomatosis Interventions: Drug: VG2025 Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer
Conditions: Unresectable/Metastatic Gastric Cancer Interventions: Drug: Sintilimab+irinotecan+leucovorin folinate+fluorouracil Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Conditions: B-Cell Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; B-Lymphocytic Leukemia, Chronic Interventions: Biological: Autologous HuCD19 ( Anti-CD19)CAR T cells; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Rituximab Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Breast and Cervical Cancer Education Program
Conditions: Cervical Cancer; Breast Cancer; Health Behavior Interventions: Other: Educational Intervention Sponsors: Johns Hopkins University; Older Women Embracing Life; The John G. Bartlett Specialty Practice Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Decade-Long Insights Into Transperineal Prostate Biopsy in a West China Population
Conditions: Prostate Cancer; Pathology Interventions: Procedure: Transperineal Prostate Biopsy Sponsors: West China Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
ERAS for Gastric Cancer Patients After NACT
Conditions: Gastric Cancer Interventions: Other: enhanced recovery after surgery; Other: conventional perioperative management Sponsors: The Affiliated Hospital of Qingdao University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
An Phase III Study, Multicenter ，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
Conditions: Bladder Cancer Interventions: Drug: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib; Drug: Tislelizumab, Cisplatin, Gemcitabine Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Babytam vs Babyexe in Post-menopausal Women at High Risk for Breast Cancer.
Conditions: Breast Cancer Interventions: Drug: Tamoxifen 10 MG; Drug: Exemestane 25 MG Sponsors: Andrea DeCensi; Dana-Farber/Brigham and Women ' s Cancer Center; Herbert Irving Comprehensive Cancer Center; Istituto Europeo di Oncologia; Breast Cancer Research Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Patient Reported Outcomes (PROs) in Anal Cancer Patient Treated by Intensity Modulated Radiotherapy (IMRT).
Conditions: Anal Cancer Patients Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
